Oblimersen

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Oblimersen 

Oblimersen 是一种针对 BCL-2 RNA 的BCL-2 抑制剂。Oblimersen 与 BCL-2 mRNA 序列的前六个密码子特异性结合，导致BCL-2 mRNA 降解，并通过下调 BCL-2 的表达诱导细胞凋亡。Oblimersen 可用于癌症研究。

Oblimersen

Oblimersen Chemical Structure

CAS No. : 190977-41-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3].

体外研究
(In Vitro)

Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro[1].
Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: Human small-cell lung cancer cell lines H69
Concentration: 500 nM
Incubation Time: 72 hours
Result: Decreased BCL-2 protein levels.

Cell Cycle Analysis[1]

Cell Line: Human small-cell lung cancer cell lines H69
Concentration: 500 nM
Incubation Time: 72 hours
Result: Arrested cell cycle at sub G1 phase.

体内研究
(In Vivo)

Oblimersen (10 mg/kg; i.p.; daily, for 6 days; nude mice bearing H69 xenografts) decreases tumoural vascularisation in vivo[1].
Oblimersen (5-10 mg/kg; i.p.; daily (Monday to Friday), for 3 weeks) has antitumor efficacy in the subcutaneous tumor model[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male severe combined immunodeficient (SCID)-RAG2 mice[2]
Dosage: 5 and 10 mg/kg
Administration: Intraperitoneal injection; daily (Monday to Friday), for 3 weeks
Result: Inhibited tumor growth in a dose-dependent manner.

CAS 号

190977-41-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Loriot Y, et, al. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Res. 2010 Oct;30(10):3869-78.

    [2]. Hu Y, et, al. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res. 2004 Nov 15;10(22):7662-70.

    [3]. Klasa RJ, et, al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务